Naoya Nishioka
Kyoto, 6028566, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 56 publications
Predictive value of TTF-1 expression for stratifying outcomes between dual ICI and chemoimmunotherapy in patients with PD-L1-negative NSCLC.
Journal: International journal of clinical oncology
Published: April 21, 2026
Baseline neutrophil-to-lymphocyte ratio predicts survival time after the initiation of nintedanib in patients with interstitial lung disease.
Journal: BMC pulmonary medicine
Published: March 11, 2026
Efficacy and safety of nintedanib for older adults with idiopathic pulmonary fibrosis or progressive fibrosing interstitial lung disease: A multicenter retrospective study in Japan.
Journal: Respiratory investigation
Published: February 26, 2026
Identification of Hidden Cachexia Subgroup in PD-L1-High NSCLC: Comparative Analysis of the AWGC vs. Fearon Criteria.
Journal: Journal of cachexia, sarcopenia and muscle
Published: November 24, 2025
Hydrostatic pressure from basal side promotes cancer proliferation, enhances migration, and alters cell polarity: A model of the effects of interstitial fluid pressure in tumor microenvironment.
Journal: Molecular biology of the cell
Published: November 19, 2025
Impact of vulnerability on concurrent chemoradiotherapy outcomes in patients with locally advanced non-small cell lung cancer using an integrated clinical trial database.
Journal: Therapeutic advances in medical oncology
Published: October 07, 2025
Prognostic factors in patients with interstitial lung disease treated with nintedanib: a multicenter retrospective study in Japan.
Journal: Scientific reports
Published: September 04, 2025
Selecting optimal immunotherapy based on inflammation in stage IV PD-L1 ≥50% gene mutation-negative non-small cell lung cancer: pembrolizumab monotherapy versus combination chemoimmunotherapy.
Journal: Translational lung cancer research
Published: July 28, 2025
Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for EGFR L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED Analysis.
Journal: JTO clinical and research reports
Published: June 16, 2025
Immune checkpoint inhibitor-induced interstitial lung disease with and without CTLA-4 regimen in non-small cell lung cancer patients and PD-L1 < 1 %: A multicenter, retrospective study.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 26, 2025
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring EGFR Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED).
Journal: Therapeutic advances in medical oncology
Published: February 07, 2025
Last Updated: 09/26/2026